Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, hitting the mark in a phase 3 trial in non-obstructive hypertrophic ...
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Today's game between O'Higgins and Sao Paulo will kick-off at May 7, 2026, 6:00 PM. We may earn a commission if you sign up through one of our links. TV channel and live stream options for O'Higgins ...
In the ACACIA-HCM trial, aficamten demonstrated a statistically significant improvement over placebo in both KCCQ-CSS (P =.021) and pVO2 (P =.003) at 36 weeks, with no new safety signals observed.
The Copa Sudamericana Group C clash between O’Higgins and Sao Paulo will take place at the Estadio El Teniente in Rancagua on Thursday, May 7, in what is a significant contest for top spot in the ...
The best time to visit São Paulo is from March to May or October to November (the fall and spring shoulder seasons) when the temperatures are comfortable, the city sees less precipitation (and less ...
Tottenham Hotspur drew 1-1 at home to Leeds on Monday as they remain deep in the relegation scrap with two games to go. MORE — Spurs vs Leeds watch full replay Mathys Tel scored early in the second ...
Fabio Wardley and Daniel Dubois will clash later this evening for the WBO heavyweight world title. The two stars will meet in front of a sell-out crowd at the Co-op Live in Manchester. Wardley won the ...
Versus Systems Inc. provides a business-to-business software platform to drive user engagement through gamification and rewards. The company offers the eXtreme Engagement Online platform, which is ...
Kale and spinach are both packed with vitamins and minerals and offer several health benefits. Kale is richer in vitamin C, while spinach has more folate and vitamins A and K. Both are rich in ...
Hosted on MSN
Cytokinetics stock rallies after pivotal heart disease study hits dual primary endpoints
Cytokinetics Inc. CYTK shares are up on Tuesday as the company announced positive topline results from its pivotal Phase 3 ACACIA-HCM trial, which met both dual primary endpoints. The trial evaluated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results